Other grades of this product :
| Neratinib Maleate Basic information |
| Product Name: | Neratinib Maleate | | Synonyms: | Neratinib Maleate;(E)-N-[4-[3-Chloro-4-[(2-pyridinyl)methoxy]anilino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide maleate;2-Butenamide, N-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-, (2E)-, (2Z)-2-butenedioate (1:1);(2E)-N-(4-{[3-Chloro-4-(2-pyridinylmethoxy)phenyl]amino}-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-2-butenamide (2Z)-2-butenedioate (1:1);Nerlynx;Neratinib Maleate USP/EP/BP;(E)-N-{4-[3-chloro-4-(pyridin-2-yl methoxy) anilino]-3-cyano-7-ethoxyquinolin-6-yl}-4-
(dimethylamino)but-2-enamide maleate;(2E)-N-(4-{[3-Chloro-4-(2-pyridinylmethoxy)phenyl]amino}-3-c... | | CAS: | 915942-22-2 | | MF: | C34H33ClN6O7 | | MW: | 673.12 | | EINECS: | 620-527-5 | | Product Categories: | | Mol File: | 915942-22-2.mol |
| Neratinib Maleate Chemical Properties |
| storage temp. | Inert atmosphere,Room Temperature |
| Neratinib Maleate Usage And Synthesis |
| Description | Neratinib (HKI-272) is a pan-HER inhibitor, this irreversible tyrosine kinase inhibitor binds and inhibits the tyrosine kinase activity of epidermal growth factor receptors, EGFR (or HER1), HER2 and HER4, which leads to reduced phosphorylation and activation of downstream signaling pathways. | | Uses | A drug used alone or with capecitabine to treat adults with certain types of HER2-positive breast cancer that have already been treated. It is also being studied in the treatment of other types of cancer. Neratinib maleate blocks certain proteins, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. | | Uses | Neratinib Maleate is a codrug; used in preparation of heterobifunctional PROTAC compounds as degraders of estrogen receptor. | | Biological Activity | Neratinib is a modified form of the discontinued compound pelitinib, and was originally being develoAdditionally, phase II development of oral neratinib as a neoadjuvant therapy for breast cancer, as a second-line therapy for non-small cell lung cancer, and for other solid tumours is also in progress in numerous countries worldwide. ped by Wyeth (later Pfizer). Oral neratinib is awaiting approval as an extended adjuvant therapy for breast cancer in the EU and in the US. Blocking HER2 function by a small molecule kinase inhibitor, such as neratinib, represents an attractive alternate strategy for the growth inhibition of HER2-positive tumours. | | Mechanism of action | Neratinib Maleate is the maleate salt form of neratinib, an orally available, quinazoline-based, irreversible inhibitor of both the receptor tyrosine kinases (RTKs) human epidermal growth factor receptor 2 (HER2; ERBB2) and human epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, neratinib targets and covalently binds to the cysteine residue in the ATP-binding pockets of both HER2 and EGFR. This inhibits their activity and results in the inhibition of downstream signal transduction events, induces cell cycle arrest, apoptosis and ultimately decreases cellular proliferation in HER2- and EGFR-expressing tumor cells. EGFR and HER2, RTKs that are mutated or overactivated in many tumor cell types, play key roles in tumor cell proliferation and tumor vascularization. |
| Neratinib Maleate Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye